Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a neurological disorder causing progressive limb weakness and numbness.
• Uncontrolled studies suggest intravenous immunoglobulin (IVIg) may be beneficial for CIDP.
• This systematic review provides an updated analysis of randomized controlled trials (RCTs) on IVIg for CIDP.

Purpose of the Study:

• To systematically review evidence from RCTs on the efficacy and safety of IVIg in treating CIDP.
• To compare IVIg with placebo, plasma exchange, and corticosteroids in CIDP patients.

Main Methods:

• Searched major databases (Cochrane, MEDLINE, EMBASE, ISI) and clinical trial registries for relevant RCTs up to December 2012.
• Included RCTs comparing any IVIg dose against placebo, plasma exchange, or corticosteroids in definite or probable CIDP.
• Two independent reviewers assessed trial quality and extracted data.

Main Results:

• Eight RCTs with 332 participants were included; overall risk of bias was low.
• IVIg significantly improved disability within one month compared to placebo (RR 2.40), with a Number Needed to Treat for Benefit (NNTB) of approximately 3.
• IVIg demonstrated similar short-term efficacy to plasma exchange, oral prednisolone, and intravenous methylprednisolone, with comparable side effect profiles. Mild transient adverse events occurred in 49% of IVIg recipients, serious events in 6%.

Conclusions:

• IVIg is effective in improving CIDP disability for at least two to six weeks compared to placebo.
• IVIg shows comparable short-term efficacy to plasma exchange and corticosteroids.
• Further research is needed to compare long-term benefits and side effects of IVIg versus other CIDP treatments.